Harnessing Microbial Recognition and Host DefenseĀ  Responses To Fight Cancer

Manhattan BioSolutions is a private biotech company focused on the discovery and development of the next-generation immunotherapy for the treatment or potential prevention of cancer. We develop novel anti-cancer therapies that leverage natural ability of innate immunity to defend human body against invading pathogens or injured cells

Scientific Platforms

Synthetic Microbes

The sMIST (SyntheticĀ Microbial Immune Stimulators) platform is based on genetically engineered microbes – “living drugs” that express immunomodulatory molecules or target mutated tumor antigens

Monoclonal Antibodies

Our novel monoclonal antibodies target Innate Immune Sensors – immunoregulatory receptors that recognize pathogens or endogenous molecules released as a result of tissue injury or inflammation

Get in touch !

If you are interested in exploring innate immunity and its translation into human therapies, or if your technology could advance the science, please contact us at ir@manhattanbiosolutions.com